Screening for Autoantibodies in Type 1 Diabetes: A Call to Action.

Abstract

• Type 1 diabetes (T1D) is an autoimmune disease that progresses through 3 distinct stages. • T1D can be diagnosed at any age, with a peak incidence at 10-14 years of age. • The incidence of T1D in the United States is rising. • Screening for T1D autoantibodies has positive clinical consequences, including reduction of diabetic ketoacidosis events, improved glycemic control, and positive impact on short- and long-term complications. • Primary care clinicians can play a critical role in promoting islet autoantibody screening.